# Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients

> **NCT05396118** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Rigshospitalet, Denmark** · enrollment: 15 (estimated)

## Conditions studied

- Breast Cancer
- Neuroendocrine Tumors
- Neuroendocrine Carcinoma
- Neuroendocrine Carcinoma Metastatic
- Lymphoma
- Sarcoma

## Interventions

- **DRUG:** 18F-FDG
- **DRUG:** Injection of hyperpolarized [1-13C]Pyruvate
- **PROCEDURE:** PET/MR/MRS/MRSI scanning

## Key facts

- **NCT ID:** NCT05396118
- **Lead sponsor:** Rigshospitalet, Denmark
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2022-05-18
- **Primary completion:** 2024-08
- **Final completion:** 2024-12
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2024-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05396118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05396118, "Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05396118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*